<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Dicerna Pharmaceuticals, Inc.

    Dicerna Pharmaceuticals, Inc.

    Dicerna is a biopharmaceutical company focused on the discovery and development of...

    Dicerna is a biopharmaceutical company focused ...

    Filing Type:    PU
    Stoke Therapeutics, Inc.

    Stoke Therapeutics, Inc.

    Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...

    Stoke is pioneering a new way to treat the unde...

    Filing Type:    PU
    Kazia Therapeutics Limited

    Kazia Therapeutics Limited

    Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...

    Kazia Therapeutics is an oncology-focused biote...

    Filing Type:    PU
    Chembio Diagnostics, Inc.

    Chembio Diagnostics, Inc.

    Chembio is a leading point-of-care diagnostics company focused on detecting and di...

    Chembio is a leading point-of-care diagnostics ...

    Filing Type:    PU
    Accuray Incorporated

    Accuray Incorporated

    Accuray develops, manufactures and sells radiation oncology systems that make canc...

    Accuray develops, manufactures and sells radiat...

    Filing Type:    PU
    Cidara Therapeutics, Inc.

    Cidara Therapeutics, Inc.

    Cidara is a clinical-stage biotechnology company focused on the discovery, develop...

    Cidara is a clinical-stage biotechnology compan...

    Filing Type:    PU
    INmune Bio Inc.

    INmune Bio Inc.

    INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...

    INmune Bio Inc. is a clinical stage biotechnolo...

    Filing Type:    PU
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...

    Atara Biotherapeutics is a leading off-the-shel...

    Filing Type:    PU
    Aravive, Inc.

    Aravive, Inc.

    Aravive is developing treatments designed to halt progression of life-threatening ...

    Aravive is developing treatments designed to ha...

    Filing Type:    PU
    ImmunoGen, Inc.

    ImmunoGen, Inc.

    ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...

    ImmunoGen is developing the next generation of ...

    Filing Type:    PU
    Benitec Biopharma Limited

    Benitec Biopharma Limited

    Benitec is a biotechnology company developing a proprietary therapeutic technology...

    Benitec is a biotechnology company developing a...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.